Complaint filed in Bihar court against Ramdev over COVID-19 medicine claim
The complainant has named Ramdev, the convenor of the Patanjali Research Institute, and his aide Balkrishna, the organisation's chairman, as accused.

The court posted the matter for hearing on June 30.
The complainant has named Ramdev, the convenor of the Patanjali Research Institute, and his aide Balkrishna, the organisation's chairman, as accused.
Hashmi submitted that Ramdev and Balkrishna claimed to have prepared "Coronil tablet" to cure COVID-19, which is nothing but misleading.
The complainant submitted that the Ayush Ministry has asked Patanjali Ayurved to stop advertising and publicising its claims about the medicine.
The Ayush Ministry has said that they have not been provided any information with regard to the details of the composition of the ayurvedic medicine, Hashmi said.
The complainant has sought registration of a case under IPC sections 420 (cheating and dishonesty inducing delivery of property), 120B (criminal conspiracy) and 270 (malignant act likely to spread infection of disease dangerous to life), among others.
Ramdev's herbal medicine company Patanjali Ayurved has launched 'Coronil tablet and Swasari vati' medicines claiming they can cure the highly contagious disease within seven days.
It has also claimed that the two Ayurveda-based medicines have shown 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system. However, the AYUSH ministry said that the facts of the claim and details of the stated scientific study are not known to it.
It has sought from the company a detailed report on composition, testing and other data of the drugs.
The ministry also used powers under a 1954 law to ask the firm to "stop advertising/publicizing" claims of corona cure drug until the issue is examined by it.
A government notification bars companies from advertising a cure without government approval. But it wasn't immediately clear if the drug can still be sold.
Ramdev said the medicines have been developed by Patanjali Research Center, Haridwar and privately-owned National Institute of Medical Science, Jaipur following all protocols with clinically controlled trial-based evidence.
Patanjali group has an estimated turnover of around Rs 10,500 crore.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.